{"entity":{"id":"epi-326","kind":"drug","name":"EPI-326","aka":[],"tldr":"EPI-326 is an experimental bispecific antibody degrader from EpiBiologics, in phase 1 trials for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma.","summary":"EPI-326 is a bispecific antibody degrader (EpiTAC) from EpiBiologics. A tissue-selective bispecific antibody that degrades both wild-type and mutant EGFR in tumours while sparing EGFR in healthy tissue. Its furthest stage is phase 1, for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07462377 recruiting; first patient dosed per company release of 19 April 2026. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"EpiBiologics: epibiologics.com","url":"https://www.epibiologics.com/pipeline"},{"label":"EpiBiologics: epibiologics.com","url":"https://www.epibiologics.com/pipeline"},{"label":"EpiBiologics: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07462377"},{"label":"ClinicalTrials.gov: trials of EPI-326","url":"https://clinicaltrials.gov/search?intr=EPI-326"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["epibiologics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07462377"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"EPI-326","modality":"Bispecific antibody degrader (EpiTAC)","mechanism":"A tissue-selective bispecific antibody that degrades both wild-type and mutant EGFR in tumours while sparing EGFR in healthy tissue.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/epi-326/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"epibiologics","kind":"company","name":"EpiBiologics","route":"/companies/epibiologics/"}],"trial":[{"id":"nct07462377","kind":"trial","name":"A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC","route":"/trials/nct07462377/"}]}}